Direct comparison
Centralized vs. Decentralized Clinical Trials
Compare centralized and decentralized clinical trial models on burden, site infrastructure, patient reach, and regulatory oversight, plus how to choose.
Ask about Centralized vs. Decentralized Clinical Trials
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do Centralized (Site-Based) Trial, Decentralized (DCT) Trial compare side by side?
The table below compares Centralized (Site-Based) Trial, Decentralized (DCT) Trial across 8 procurement-relevant dimensions, from where study visits happen through best-fit trial characteristics.
Side-by-side comparison
| Dimension | Centralized (Site-Based) Trial | Decentralized (DCT) Trial |
|---|---|---|
| Where study visits happen | Participants travel to a limited number of investigator sites for all or nearly all protocol procedures. | Some or all visits occur remotely: telehealth, local labs/imaging, home health providers, or the participant's own home. |
| Regulatory framework | Same IND/IDE, ICH GCP (E6(R3)), Common Rule/21 CFR 50, safety-reporting requirements. | Identical framework — FDA's Sept. 2024 final guidance applies existing rules to off-site activities, not a separate DCT pathway. |
| Site infrastructure required | Full on-site capacity at each site: exam space, IMP storage/pharmacy, phlebotomy/imaging, dedicated clinical staff. | Reduced per-site footprint, but requires a DtP-capable supply chain, Part 11-compliant remote data/eConsent tech, and a local/telehealth provider network. |
| Administrative burden | Concentrated and duplicated at each site: contracts, budgets, essential documents, scheduling per site. | Shifts substantially to sponsor-level vendor qualification and oversight of home-health, courier, and technology vendors. |
| Patient population reach | Limited to participants able to travel repeatedly to a site; can underrepresent rural/mobility-limited populations. | Can widen geographic and demographic reach, useful for rare-disease/dispersed populations — but depends on participant internet access and tech comfort. |
| IRB/ethics review focus | Reviews procedures occurring within one site's physical and staffing environment. | Additionally evaluates delegation to remote/local providers, eConsent comprehension safeguards, and remote safety monitoring. |
| Monitoring approach | In-person source data verification during scheduled site monitoring visits, tracked via CTMS. | Adds remote monitoring, wearable/digital-health data streams, and eCOA reconciliation against endpoints — typically needs a risk-based monitoring plan. |
| Best-fit trial characteristics | Complex procedures, in-clinic-only administration, intensive acute monitoring, first-in-human dosing. | Simple, well-characterized administration; low acute-risk profile; procedures a participant or local provider can safely perform. |
Common questions
Common questions about Centralized (Site-Based) Trial vs Decentralized (DCT) Trial
Can a trial mix centralized and decentralized elements?
+
Yes — this is the norm rather than the exception. FDA's guidance treats decentralization as a set of elements that can be layered onto specific protocol procedures rather than a wholesale alternative design; most real-world DCTs are hybrids.
Does running a decentralized trial require separate FDA approval?
+
No. DCTs operate under the same IND/IDE and GCP framework as centralized trials. FDA's September 2024 final guidance explains how to apply existing requirements when specific activities occur away from a traditional site — it does not create a separate DCT regulatory pathway.
Which model is cheaper?
+
It depends on the protocol and population. Decentralized elements can reduce physical-site costs and travel-related dropout, but add technology, logistics, and vendor-oversight costs. The comparison has to be made procedure by procedure, not assumed in either direction.
Is a decentralized model appropriate for every therapeutic area?
+
No. Trials involving complex procedures, in-clinic-only administration, or intensive acute monitoring generally remain centralized for those specific visits, even within an otherwise hybrid design.
